It was reported via journal article: title: long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux.Authors: robert a.Ganz, steven a.Edmundowicz, paul a.Taiganides, john c.Lipham, c.Daniel smith, kenneth r.Devault, santiago horgan, garth jacobsen, james d.Luketich, christopher c.Smith, steven c.Schlack-haerer, shanu n.Kothari, christy m.Dunst, thomas j.Watson, jeffrey peters, brant k.Oelschlager, kyle a.Perry, scott melvin, willem a.Bemelman, andré j.P.M.Smout, dan dunn.Citation: clinical gastroenterology and hepatology.2016; 14: 671¿677.Doi: http://dx.Doi.Org/10.1016/j.Cgh.2015.05.028.Based on results from year 2 of a 5-year trial, in 2012 the us food and drug administration approved the use of a magnetic device to augment lower esophageal sphincter function in patients with gastroesophageal reflux disease (gerd).The authors reported the final results of 5 years of follow-up evaluation of patients who received this device.The authors performed a prospective study of the safety and efficacy of a magnetic device in 100 adults (52% male and 48% female patients; age range: 18 to 75 years old; bmi: 20 to 35) with gerd for 6 months or more, who were partially responsive to daily proton pump inhibitors (ppis) and had evidence of pathologic esophageal acid exposure, at 14 centers in the united states and the netherlands.The placement of a magnetic sphincter augmentation device (linx reflux management system; ethicon) is the only antireflux procedure that mechanically restores competency to the reflux barrier without using the gastric fundus.Reported complications included de novo esophagitis (n-5), persistent dysphagia (n-4) which required device removal with resolution after removal, persistent reflux symptoms (n-1) which required device removal , and persistent chest pain (n-1) which required device removal.In conclusion, this study showed that patients with chronic gerd and failed long-term ppi therapy benefited from surgical intervention with magnetic sphincter augmentation.Long-term safety and efficacy have been validated for this procedure.It should be considered a first-line therapy for patients and physicians seeking a fundic-sparing antireflux procedure.
|